Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0EFQS)

• Drug Name: Plasminogen Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2/3	[1]
Congenital plasminogen activator inhibitor type 1 deficiency	3B50.1	Phase 2/3	[2]
Hypoplasminogenemia	DA0D.3	Phase 2/3	[2]

• Cross-matching ID: TTD Drug ID: DM0EFQS

Molecule-Related Drug Atlas

Drug(s) Targeting Plasminogen (PLG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranolazine	DM0C9IL	Acute coronary syndrome	BA41	Approved	[4]
Aminocaproic Acid	DMFGND4	Bleeding disorder	GA20-GA21	Approved	[5]
Streptokinase	DM5JQ0D	Pulmonary embolism	BB00	Approved	[6]
Tranexamic Acid	DMFI8A7	Excessive bleeding	GA30.02	Approved	[7]
Alteplase	DMRJ3YX	Acute myocardial infarction	BA41	Approved	[8]
Tenecteplase	DMJYN25	Acute myocardial infarction	BA41	Approved	[8]
Anistreplase	DM6Q4B0	Acute coronary syndrome	BA41	Approved	[9]
Reteplase	DML0D1P	Heart attack	BA41	Approved	[10]
MELAGATRAN	DM4W8RE	N. A.	N. A.	Phase 3	[11]
Desmoteplase	DMDLU4Z	Ischemic stroke	8B11.5Z	Phase 3	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Plasminogen (PLG)	TTP86E2	PLMN_HUMAN	Modulator	[3]

References

• [1] ClinicalTrials.gov (NCT01554956) Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Structure and function of the plasminogen/plasmin system. Thromb Haemost. 2005 Apr;93(4):647-54.
• [4] Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
• [5] The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92.
• [6] Acute anuric renal failure with streptokinase therapy in a patient with acute venous thromboembolic disease and the review of renal side effects of streptokinase. Tuberk Toraks. 2008;56(4):456-61.
• [7] Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8.
• [8] Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32.
• [9] Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7.
• [10] Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.
• [11] Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
• [12] Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43.